Study of a new drug for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must have gotten worse after at least one prior treatment.
- You need to have at least one tumor that can be measured on a CT or MRI scan.
- You must be able to provide a tumor sample (either a fresh biopsy or an archived sample from the past 5 years).
- Your cancer type must be one of the specific types listed in the study (e.g., endometrial, head and neck, pancreatic, colorectal, liver, stomach, bladder, cervical, ovarian, bile duct, breast, melanoma, or neuroendocrine).
- You must not have certain serious conditions, like active brain metastases or a history of lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.